Long-term follow-up of implantable cardioverter-defibrillators in children: Indications and outcomes

被引:4
|
作者
Kwiatkowska, Joanna [1 ]
Budrejko, Szymon [2 ]
Wasicionek, Marek [3 ]
Meyer-Szary, Jaroslaw [1 ]
Lubinski, Andrzej [4 ]
Kempa, Maciej [2 ]
机构
[1] Med Univ Gdansk, Dept Pediat Cardiol & Congenital Heart Defect, Gdansk, Poland
[2] Med Univ Gdansk, Dept Cardiol & Electrotherapy 2, Gdansk, Poland
[3] Wroclaw Med Univ, Dept & Clin Pediat Allergol & Cardiol 1, Wroclaw, Poland
[4] Med Univ Lodz, Dept Intervent Cardiol & Cardiac Arrhythmias, Lodz, Poland
来源
关键词
sudden cardiac death; implantable cardioverter-defibrillator; pediatric cardiology; SUDDEN CARDIAC DEATH; YOUNG-ADULTS; VENTRICULAR-ARRHYTHMIAS; HEART; GUIDELINES; PREVENTION; THERAPY; FAILURE; DEVICES; MANAGEMENT;
D O I
10.17219/acem/110313
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background. Validation data of the use of implantable cardioverter-defibrillators (ICD) in the pediatric population is insufficient, with limited follow-up periods. Objectives. The aim of the study was to report on 17 years of experience with implantable cardioverter-defibrillator (ICD) therapy in children and young adults. Materials and methods. This retrospective review included patients below the age of 18 years at the time of ICD implantation between May 2000 and December 2017. For the statistical analysis, the sample was divided into groups by gender and the type of indications for ICD implantation (primary vs secondary prevention). Results. The study group included 20 children (8 female, 12 male) who underwent ICD implantation for primary or secondary prevention of sudden cardiac death (SCD). The average age at the time of the initial procedure was 15.6 years (range: 3.8-17.7 years). Primary electrical disease (PED) was present in 9 patients, cardiomyopathy (CMP) in 9 and 2 others had congenital heart defects (CHD5). The median follow-up time was 6.7 years (range: 0.4-12.5 years). The outcomes of ICD therapy were analyzed. No differences between the sexes were found in terms of treatment strategy effectiveness (p > 0.05). The girls were more often treated as primary prevention (p = 0.009). After implantation, all the patients were on optimal pharmacotherapy. Alltogether there were 126 ICD interventions in 11 patients, including 23 inadequate interventions (IA) in 2 children (18.2%).Three children (15%) died due to electrical storms. In the per-procedure analysis, the overall freedom rate from ICD lead replacement was 90%, 80%, and 57% at 1, 5 and 10 years of observation, respectively. Conclusions. Implantable cardioverter-defibrillator implantation indications in children are more heterogeneous in comparison to adult population. In the pediatric population undergoing ICD implantation, the treatment strategy is influenced by gender. The rate of inappropriate ICD discharges (IA) in our group of pediatric patients was low. Rigorous pharmacotherapy and individual ICD programming seemed of paramount importance. Lead malfunctions LF constituted the most prevalent complication observed.
引用
收藏
页码:123 / 133
页数:11
相关论文
共 50 条
  • [21] Long-term follow-up on high-rate cutoff programming for implantable cardioverter defibrillators
    Clementy, N.
    Pierre, B.
    Lallemand, B.
    Marie, O.
    Lemoine, E.
    Cosnay, P.
    Fauchier, L.
    Babuty, D.
    EUROPEAN HEART JOURNAL, 2011, 32 : 307 - 307
  • [22] Long-Term Clinical Outcomes in Young Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators
    Burrows, Austin
    Madias, Christopher
    Rowin, Ethan J.
    Maron, Martin S.
    Maron, Barry J.
    CIRCULATION, 2019, 140
  • [23] Implantable Cardioverter-Defibrillators Indications and Unresolved Issues
    Kedia, Rohit
    Saeed, Mohammad
    TEXAS HEART INSTITUTE JOURNAL, 2012, 39 (03): : 335 - 341
  • [24] Implantable cardioverter-defibrillators - Expanding indications and technologies
    Goldberger, Z
    Lampert, R
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (07): : 809 - 818
  • [25] Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study
    Lambiase, Pier D.
    Theuns, Dominic A.
    Murgatroyd, Francis
    Barr, Craig
    Eckardt, Lars
    Neuzil, Petr
    Scholten, Marcoen
    Hood, Margaret
    Kuschyk, Jurgen
    Brisben, Amy J.
    Carter, Nathan
    Stivland, Timothy M.
    Knops, Reinoud
    Boersma, Lucas V. A.
    EUROPEAN HEART JOURNAL, 2022, 43 (21) : 2037 - 2050
  • [26] ADVERSE EVENTS IN RECIPIENTS OF IMPLANTABLE CARDIOVERTER DEFIBRILLATORS DURING LONG-TERM FOLLOW-UP: GENDER IMPACT
    Qi, A.
    Chakrabarti, S.
    Tung, S. K.
    Flavelle, S.
    McIlroy, C.
    Yeung-Lai-Wah, J. A.
    Kerr, C. R.
    CANADIAN JOURNAL OF CARDIOLOGY, 2010, 26 : 132D - 132D
  • [27] Long-term outcomes of subcutaneous implantable cardioverter-defibrillators: a single-centre Australian experience
    Mahmoodi, Ehsan
    Lee, Xiang Wen
    Freeman, Blake M.
    Webster, Meghan A.
    Betts, John R.
    Haqqani, Haris M.
    Denman, Russell A.
    INTERNAL MEDICINE JOURNAL, 2025,
  • [28] Economic outcomes of implantable cardioverter-defibrillators
    Stanton, MS
    Bell, GK
    CIRCULATION, 2000, 101 (09) : 1067 - 1074
  • [29] IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS IN INFANTS AND TODDLERS: INDICATIONS, PLACEMENT, PROGRAMMING AND OUTCOMES
    Zahedivash, Aydin
    Hanisch, Debra
    Dubin, Anne M.
    Trela, Anthony V.
    Chubb, Henry
    Motonaga, Kara
    Goodyer, William
    Maeda, Katsuhide
    Reinhartz, Olaf
    Ceresnak, Scott
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 470 - 470
  • [30] Information provision and follow-up of French patients with implantable cardioverter-defibrillators: The APODEC survey
    Halin, Anais
    Hamelin, Jean-Luc
    Defaye, Pascal
    Deharo, Jean-Claude
    Fauchier, Laurent
    Marijon, Eloi
    Piot, Olivier
    Boveda, Serge
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2023, 116 (12) : 572 - 579